Overview

A Phase 3 Trial of OPA-15406 Foam in Children and Infants With Atopic Dermatitis

Status:
NOT_YET_RECRUITING
Trial end date:
2027-02-01
Target enrollment:
Participant gender:
Summary
To investigate the superiority of 0.3% OPA-15406 foam to the vehicle in children with atopic dermatitis (AD)
Phase:
PHASE3
Details
Lead Sponsor:
Otsuka Pharmaceutical Co., Ltd.
Treatments:
difamilast